Ico Therapeutics Inc., of Vancouver, British Columbia, disclosed the final, eight-month patient visit in the phase II iDEAL study. The investigator-sponsored study is evaluating the efficacy and safety of ICO-007 after repeated injections in patients with diabetic macular edema.